Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 254, pseudogene (RNU6-254P) is a *processed pseudogene* of the U6 small nuclear RNA (snRNA) family[4]. U6 snRNA itself is an essential non-coding RNA component of the spliceosome, playing a central role in nuclear mRNA splicing[1][5]. However, RNU6-254P, being a pseudogene, is considered a genetically inactive remnant and is not thought to produce a functional RNA or protein product[4]. As a pseudogene, it does not encode a receptor, enzyme, transporter, or other canonical drug target, nor is it implicated as a therapeutic target or biomarker in current biomedical literature. Pseudogenes like RNU6-254P are sometimes of interest for studies of genome evolution or, in rare cases, regulatory RNA functions[2], but specific functions or disease associations for RNU6-254P have not been reported in available sources.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 254, pseudogene (RNU6-254P).